Skip to main content
C
CorpDigest
Search

McKesson Corporation

Healthcare Distribution and ServicesFounded 1833
Reviewed by Swet Parvadiya
Company data updated: October 2026

Leadership History

McKesson: CEO History

2 leaders · 2001 to present

Who is the CEO of McKesson?

Brian S. Tyler is the CEO of McKesson, in the role since 2019. The first chief executive was John Hammergren, from 2001.

Current CEO
Brian S. Tyler (since 2019)
First CEO
John Hammergren (2001)
Leaders documented
2
Founded
1833
NameRoleFromToYears in role
Brian S. TylerChief Executive Officer2019Present7
John HammergrenChief Executive Officer2001201918
Who was CEO of McKesson before Brian S. Tyler?
John Hammergren was CEO of McKesson from 2001 to 2019, before Brian S. Tyler took over in 2019.

Company Overview

McKesson is best understood as healthcare infrastructure. It moves medicines through a regulated network and supports providers and manufacturers with specialty distribution, oncology services, patient-access programs, technology, and medical supplies. The strategic shift is toward higher-growth oncology, multispecialty, and biopharma services while simplifying the portfolio through the European exit and planned Medical-Surgical separation.

McKesson makes money primarily by purchasing and distributing pharmaceuticals and medical products to pharmacies, hospitals, health systems, and other providers. Distribution is a high-volume, thin-margin business, so purchasing terms, logistics efficiency, order accuracy, customer contracts, and working-capital management drive results. The company also earns service revenue through oncology and multispecialty provider platforms, biopharma services, prescription access and affordability tools, third-party logistics, and medical-surgical distribution.

Brian S. Tyler

Chief Executive Officer

2019 – Present

7 years (current)

Key Decisions & Impact

Exit European distribution; acquire controlling stakes in Florida Cancer Specialists' Core Ventures and PRISM Vision; sell a minority stake in Medical-Surgical Solutions to Apollo ahead of separation.

Legacy

CEO since April 2019. Tyler led the 2022 opioid settlement, the exit from Europe, the shift toward oncology, multispecialty and biopharma services, and the plan to separate Medical-Surgical Solutions as Wellverse. Revenue grew from $214.3 billion in fiscal 2019 to $403.4 billion in fiscal 2026.

Source →

John Hammergren

Chief Executive Officer

2001 – 2019

18 years

Key Decisions & Impact

Hammergren executed an absolutely massive, aggressive acquisition spree (buying massive European distributors like Celesio) to transform McKesson from a US wholesaler into a global healthcare behemoth.

Legacy

Serving as CEO from 2001 to 2019, he became one of the absolute highest-paid executives in American history, driving massive shareholder returns but presiding over the company during the height of the catastrophic opioid distribution crisis.

Source →

Challenges & Strategic Context

McKesson must manage customer concentration, policy changes affecting drug pricing and 340B arrangements, opioid-related claims, cybersecurity, acquisition integration, and the planned separation of Medical-Surgical Solutions while maintaining high service levels across a low-margin network.

McKesson CEO and Leadership FAQ

Who was John Hammergren and what was his impact as McKesson's long-serving CEO?

John Hammergren served as Chairman and CEO of McKesson from 2001 to 2019, presiding over one of the most successful eras in corporate history. Under his leadership, McKesson expanded from $42 billion to over $214 billion in revenue, acquired US Oncology, Celesio (Europe), and CoverMyMeds, and transformed McKesson into a healthcare services leader.

What major strategic transformations has CEO Brian Tyler executed since 2019?

Since becoming CEO in April 2019, Brian Tyler streamlined McKesson's operating structure, orchestrated the full divestiture of capital-intensive European retail assets, navigated McKesson's centralized role in federal COVID-19 vaccine distribution, finalized the nationwide opioid settlement, and deepened investments in specialty oncology and digital biopharma solutions.

How did McKesson manage executive leadership succession from Hammergren to Tyler?

McKesson executed a planned, smooth multi-year succession by elevating Brian Tyler, who had spent over two decades leading McKesson's Medical-Surgical, European, and US Pharmaceutical divisions as COO, ensuring institutional continuity with major health system customers and pharmaceutical partners.

What historic leadership scandal occurred at McKesson & Robbins in 1938?

In 1938, McKesson & Robbins was rocked by a large financial fraud orchestrated by its CEO, Philip Musica (operating under the alias F. Donald Coster), who had fabricated $19 million in non-existent crude drug inventories and shell companies. The scandal led to major SEC accounting reforms, including mandatory independent auditor physical inventory verifications.

How did Brian Tyler reorganize McKesson's executive committee around oncology and specialty care?

Brian Tyler established dedicated executive leadership units for Oncology and Multispecialty Services, appointing specialized clinical and operational leaders to accelerate acquisitions of cancer center management service organizations (MSOs) and integrate advanced genomics into community clinics.

What compensation governance reforms did McKesson's board implement under shareholder scrutiny?

Following shareholder advisory votes in the mid-2010s regarding executive compensation and opioid legal liabilities, McKesson's board restructured incentive compensation formulas, tying executive bonuses directly to ESG metrics, opioid compliance audits, and adjusted operating cash flow metrics.

How did McKesson's leadership respond to the federal government's call during the 2020 pandemic?

CEO Brian Tyler and his supply chain leadership mobilized McKesson's logistics network within weeks under Operation Warp Speed, setting up dedicated kitting and distribution facilities that delivered hundreds of millions of vaccines with a 99.9% on-time delivery rate.

What is Brian Tyler's vision for McKesson's long-term digital health strategy?

Brian Tyler envisions McKesson as the indispensable digital and physical orchestrator of the healthcare ecosystem, connecting pharmaceutical manufacturers, doctors, and payers through automated software to reduce the time it takes for patients to receive life-saving specialty medications.

Who is the CEO of McKesson?

Brian Tyler serves as CEO, taking over in 2019. He succeeded John Hammergren, who was highly infamous for being one of the absolute highest-paid CEOs in America (often making over $50 million a year). Tyler's absolute primary mandate was cleaning up the massive legal liability of the opioid crisis and aggressively expanding McKesson's highly lucrative US Oncology Network.

Related Leadership Timelines

Compare executive leadership tenures and strategic transitions

Competitor

Cencora

View Leadership Timelines
Competitor

Cardinal Health

View Leadership Timelines
Competitor

Cvs Health

View Leadership Timelines
Competitor

Unitedhealth

View Leadership Timelines
Competitor

Walgreens Boots Alliance

View Leadership Timelines
Competitor

Walmart

View Leadership Timelines

Explore McKesson

Core profile pages, founders and related research hubs for this company.

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.